Goldman Sachs Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has downgraded Revance Therapeutics (RVNC) from Buy to Neutral and reduced the price target from $30 to $8.

January 09, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics' stock rating has been downgraded by Goldman Sachs from Buy to Neutral, with a significant reduction in price target from $30 to $8.
The downgrade by a major financial institution like Goldman Sachs can have a negative impact on investor sentiment towards RVNC, likely leading to a short-term decline in the stock price. The substantial decrease in the price target suggests a revision of the expected performance or value of the company, which can further affect the stock negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100